Abnormal accumulation of dysfunctional p53 protein in cancer cells has been attempted to be utilized for a therapeutic advantage with p53 DC vaccines to train T cells to recognize and activate against the excess p53 epitopes displaced on MHC Class I/II. The gene discussed is TP53; the disease is cancer.